Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Deferred Tax Liability (2023 - 2025)

Historic Non-Current Deferred Tax Liability for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q3 2025 value amounting to $31.7 million.

  • Iovance Biotherapeutics' Non-Current Deferred Tax Liability changed N/A to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.7 million, marking a year-over-year change of. This contributed to the annual value of $32.3 million for FY2024, which is 8628.58% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Non-Current Deferred Tax Liability is $31.7 million.
  • In the past 5 years, Iovance Biotherapeutics' Non-Current Deferred Tax Liability ranged from a high of $34.7 million in Q2 2025 and a low of $17.3 million during Q4 2023
  • Its 3-year average for Non-Current Deferred Tax Liability is $27.5 million, with a median of $31.8 million in 2025.
  • In the last 5 years, Iovance Biotherapeutics' Non-Current Deferred Tax Liability surged by 8628.58% in 2024 and then crashed by 402.09% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Non-Current Deferred Tax Liability stood at $17.3 million in 2023, then skyrocketed by 86.29% to $32.3 million in 2024, then fell by 2.01% to $31.7 million in 2025.
  • Its Non-Current Deferred Tax Liability stands at $31.7 million for Q3 2025, versus $34.7 million for Q2 2025 and $32.0 million for Q1 2025.